Marketplace Roundtable: Biotech Hanging In The Balance


As Capitol Hill swirls around the possibility of a new healthcare bill, biotech investors would do well to keep an eye on developments. But there are other areas of the industry to focus on, whether M&A activity, oncology progress, CRISPR innovations, or plain old mean reversion.



from Biotech News